North Chicago-based Abbvie Inc. (ABBV), with a market cap of $277.3 billion, is a global pharmaceutical leader with solid exposure to immunology with drugs like Humira, Skyrizi, and Rinvoq, and oncology with Imbruvica and Venclexta. The company’s 2020 acquisition of Allergan significantly boosted its prominence in the pharma sector by adding several new products and drugs in aesthetics, including Botox.
Shares of the pharma giant have lagged behind the broader market in the last year. While ABBV has surged 11.3% over this time frame, the broader S&P 500 Index ($SPX) has rallied by 28.9%. In 2024, the stock rose 1.4%, compared to SPX’s 11.2% return on a YTD basis.
